       Document 0766
 DOCN  M9440766
 TI    Interferon decreases serum lipid peroxidation products of hepatitis C
       patients.
 DT    9404
 AU    Higueras V; Raya A; Rodrigo JM; Serra MA; Roma J; Romero FJ; Department
       of Physiology, School of Medicine and Dentistry,; University of
       Valencia, Spain.
 SO    Free Radic Biol Med. 1994 Jan;16(1):131-3. Unique Identifier : AIDSLINE
       MED/94131330
 AB    Thiobarbituric acid reactive substances (TBARS) concentration in serum
       has been determined in healthy subjects and in patients suffering acute
       hepatitis and chronic cases of hepatitis C. Treatment with interferon of
       the chronic active hepatitis C patients, 5 x 10(6) U three times a week
       during 2 months, led in those patients whose SGPT activity normalized in
       serum, to a concomitant decrease in serum TBARS content. The possible
       theoretical involvement of peroxidation and antioxidants in this
       beneficial effect of interferon in hepatitis C patients is discussed.
       The results presented confirm the value of TBARS as laboratory test in
       the management of liver diseases and as a useful tool for the study of
       pathogenic and/or therapeutic mechanisms of this viral infection.
 DE    Acute Disease  Hepatitis/BLOOD/*THERAPY  Hepatitis C/BLOOD/*THERAPY
       Hepatitis, Chronic Active/BLOOD/*THERAPY  Human  HIV Infections/BLOOD
       Interferons/*THERAPEUTIC USE  *Lipid Peroxidation  Lipids/*BLOOD
       Superoxide Dismutase/METABOLISM  Support, Non-U.S. Gov't  Thiobarbituric
       Acid Reactive Substances/METABOLISM  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

